Open- | Close- |
Vol / Avg.1.751K / 2.327M | Mkt Cap3.170M |
Day Range- - - | 52 Wk Range0.605 - 8.700 |
NeuBase Therapeutics Stock (NASDAQ: NBSE) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.1.751K / 2.327M | Mkt Cap3.170M |
Day Range- - - | 52 Wk Range0.605 - 8.700 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2022-10-21 | Oppenheimer | Hartaj Singh | Downgrades | OutperformPerform | - | - | - |
2022-10-18 | RBC Capital | Leonid Timashev | Downgrades | OutperformSector Perform | Lowers | 12.00 | 1.00 |
2022-10-17 | Chardan Capital | Keay Nakae | Downgrades | BuyNeutral | - | - | - |
2022-08-12 | Chardan Capital | Keay Nakae | Maintains | Buy | Lowers | 9.00 | 7.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
NBSE | NeuBase Therapeutics | -2.28% | 3.2M |
PSTV | Plus Therapeutics | -5.22% | 3.7M |
PBLA | Panbela Therapeutics | -1.53% | 3.8M |
THAR | Tharimmune | -7.5% | 3.3M |
DRMA | Dermata Therapeutics | 0.94% | 3.4M |
You can purchase shares of NeuBase Therapeutics (NASDAQ: NBSE) through any online brokerage.
Other companies in NeuBase Therapeutics’s space includes: Plus Therapeutics (NASDAQ:PSTV), Panbela Therapeutics (NASDAQ:PBLA), Tharimmune (NASDAQ:THAR), Dermata Therapeutics (NASDAQ:DRMA) and Biocept (NASDAQ:BIOC).
The latest price target for NeuBase Therapeutics (NASDAQ: NBSE) was reported by Oppenheimer on Friday, October 21, 2022. The analyst firm set a price target for 0.00 expecting NBSE to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
The stock price for NeuBase Therapeutics (NASDAQ: NBSE) is $0.85 last updated Today at October 2, 2023 at 9:06 AM UTC.
There is no dividend information for NeuBase Therapeutics.
NeuBase Therapeutics’s Q4 earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for NeuBase Therapeutics.
NeuBase Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
NeuBase Therapeutics Stock (NASDAQ: NBSE) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.1.751K / 2.327M | Mkt Cap3.170M |
Day Range- - - | 52 Wk Range0.605 - 8.700 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2022-10-21 | Oppenheimer | Hartaj Singh | Downgrades | OutperformPerform | - | - | - |
2022-10-18 | RBC Capital | Leonid Timashev | Downgrades | OutperformSector Perform | Lowers | 12.00 | 1.00 |
2022-10-17 | Chardan Capital | Keay Nakae | Downgrades | BuyNeutral | - | - | - |
2022-08-12 | Chardan Capital | Keay Nakae | Maintains | Buy | Lowers | 9.00 | 7.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
NBSE | NeuBase Therapeutics | -2.28% | 3.2M |
PSTV | Plus Therapeutics | -5.22% | 3.7M |
PBLA | Panbela Therapeutics | -1.53% | 3.8M |
THAR | Tharimmune | -7.5% | 3.3M |
DRMA | Dermata Therapeutics | 0.94% | 3.4M |
You can purchase shares of NeuBase Therapeutics (NASDAQ: NBSE) through any online brokerage.
Other companies in NeuBase Therapeutics’s space includes: Plus Therapeutics (NASDAQ:PSTV), Panbela Therapeutics (NASDAQ:PBLA), Tharimmune (NASDAQ:THAR), Dermata Therapeutics (NASDAQ:DRMA) and Biocept (NASDAQ:BIOC).
The latest price target for NeuBase Therapeutics (NASDAQ: NBSE) was reported by Oppenheimer on Friday, October 21, 2022. The analyst firm set a price target for 0.00 expecting NBSE to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
The stock price for NeuBase Therapeutics (NASDAQ: NBSE) is $0.85 last updated Today at October 2, 2023 at 9:06 AM UTC.
There is no dividend information for NeuBase Therapeutics.
NeuBase Therapeutics’s Q4 earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for NeuBase Therapeutics.
NeuBase Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
NeuBase Therapeutics Stock (NASDAQ: NBSE) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.1.751K / 2.327M | Mkt Cap3.170M |
Day Range- - - | 52 Wk Range0.605 - 8.700 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2022-10-21 | Oppenheimer | Hartaj Singh | Downgrades | OutperformPerform | - | - | - |
2022-10-18 | RBC Capital | Leonid Timashev | Downgrades | OutperformSector Perform | Lowers | 12.00 | 1.00 |
2022-10-17 | Chardan Capital | Keay Nakae | Downgrades | BuyNeutral | - | - | - |
2022-08-12 | Chardan Capital | Keay Nakae | Maintains | Buy | Lowers | 9.00 | 7.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
NBSE | NeuBase Therapeutics | -2.28% | 3.2M |
PSTV | Plus Therapeutics | -5.22% | 3.7M |
PBLA | Panbela Therapeutics | -1.53% | 3.8M |
THAR | Tharimmune | -7.5% | 3.3M |
DRMA | Dermata Therapeutics | 0.94% | 3.4M |
You can purchase shares of NeuBase Therapeutics (NASDAQ: NBSE) through any online brokerage.
Other companies in NeuBase Therapeutics’s space includes: Plus Therapeutics (NASDAQ:PSTV), Panbela Therapeutics (NASDAQ:PBLA), Tharimmune (NASDAQ:THAR), Dermata Therapeutics (NASDAQ:DRMA) and Biocept (NASDAQ:BIOC).
The latest price target for NeuBase Therapeutics (NASDAQ: NBSE) was reported by Oppenheimer on Friday, October 21, 2022. The analyst firm set a price target for 0.00 expecting NBSE to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
The stock price for NeuBase Therapeutics (NASDAQ: NBSE) is $0.85 last updated Today at October 2, 2023 at 9:06 AM UTC.
There is no dividend information for NeuBase Therapeutics.
NeuBase Therapeutics’s Q4 earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for NeuBase Therapeutics.
NeuBase Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
NeuBase Therapeutics Stock (NASDAQ: NBSE) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.1.751K / 2.327M | Mkt Cap3.170M |
Day Range- - - | 52 Wk Range0.605 - 8.700 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2022-10-21 | Oppenheimer | Hartaj Singh | Downgrades | OutperformPerform | - | - | - |
2022-10-18 | RBC Capital | Leonid Timashev | Downgrades | OutperformSector Perform | Lowers | 12.00 | 1.00 |
2022-10-17 | Chardan Capital | Keay Nakae | Downgrades | BuyNeutral | - | - | - |
2022-08-12 | Chardan Capital | Keay Nakae | Maintains | Buy | Lowers | 9.00 | 7.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
NBSE | NeuBase Therapeutics | -2.28% | 3.2M |
PSTV | Plus Therapeutics | -5.22% | 3.7M |
PBLA | Panbela Therapeutics | -1.53% | 3.8M |
THAR | Tharimmune | -7.5% | 3.3M |
DRMA | Dermata Therapeutics | 0.94% | 3.4M |
You can purchase shares of NeuBase Therapeutics (NASDAQ: NBSE) through any online brokerage.
Other companies in NeuBase Therapeutics’s space includes: Plus Therapeutics (NASDAQ:PSTV), Panbela Therapeutics (NASDAQ:PBLA), Tharimmune (NASDAQ:THAR), Dermata Therapeutics (NASDAQ:DRMA) and Biocept (NASDAQ:BIOC).
The latest price target for NeuBase Therapeutics (NASDAQ: NBSE) was reported by Oppenheimer on Friday, October 21, 2022. The analyst firm set a price target for 0.00 expecting NBSE to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
The stock price for NeuBase Therapeutics (NASDAQ: NBSE) is $0.85 last updated Today at October 2, 2023 at 9:06 AM UTC.
There is no dividend information for NeuBase Therapeutics.
NeuBase Therapeutics’s Q4 earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for NeuBase Therapeutics.
NeuBase Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
NeuBase Therapeutics Stock (NASDAQ: NBSE) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.1.751K / 2.327M | Mkt Cap3.170M |
Day Range- - - | 52 Wk Range0.605 - 8.700 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2022-10-21 | Oppenheimer | Hartaj Singh | Downgrades | OutperformPerform | - | - | - |
2022-10-18 | RBC Capital | Leonid Timashev | Downgrades | OutperformSector Perform | Lowers | 12.00 | 1.00 |
2022-10-17 | Chardan Capital | Keay Nakae | Downgrades | BuyNeutral | - | - | - |
2022-08-12 | Chardan Capital | Keay Nakae | Maintains | Buy | Lowers | 9.00 | 7.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
NBSE | NeuBase Therapeutics | -2.28% | 3.2M |
PSTV | Plus Therapeutics | -5.22% | 3.7M |
PBLA | Panbela Therapeutics | -1.53% | 3.8M |
THAR | Tharimmune | -7.5% | 3.3M |
DRMA | Dermata Therapeutics | 0.94% | 3.4M |
You can purchase shares of NeuBase Therapeutics (NASDAQ: NBSE) through any online brokerage.
Other companies in NeuBase Therapeutics’s space includes: Plus Therapeutics (NASDAQ:PSTV), Panbela Therapeutics (NASDAQ:PBLA), Tharimmune (NASDAQ:THAR), Dermata Therapeutics (NASDAQ:DRMA) and Biocept (NASDAQ:BIOC).
The latest price target for NeuBase Therapeutics (NASDAQ: NBSE) was reported by Oppenheimer on Friday, October 21, 2022. The analyst firm set a price target for 0.00 expecting NBSE to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
The stock price for NeuBase Therapeutics (NASDAQ: NBSE) is $0.85 last updated Today at October 2, 2023 at 9:06 AM UTC.
There is no dividend information for NeuBase Therapeutics.
NeuBase Therapeutics’s Q4 earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for NeuBase Therapeutics.
NeuBase Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
NeuBase Therapeutics Stock (NASDAQ: NBSE) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.1.751K / 2.327M | Mkt Cap3.170M |
Day Range- - - | 52 Wk Range0.605 - 8.700 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2022-10-21 | Oppenheimer | Hartaj Singh | Downgrades | OutperformPerform | - | - | - |
2022-10-18 | RBC Capital | Leonid Timashev | Downgrades | OutperformSector Perform | Lowers | 12.00 | 1.00 |
2022-10-17 | Chardan Capital | Keay Nakae | Downgrades | BuyNeutral | - | - | - |
2022-08-12 | Chardan Capital | Keay Nakae | Maintains | Buy | Lowers | 9.00 | 7.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
NBSE | NeuBase Therapeutics | -2.28% | 3.2M |
PSTV | Plus Therapeutics | -5.22% | 3.7M |
PBLA | Panbela Therapeutics | -1.53% | 3.8M |
THAR | Tharimmune | -7.5% | 3.3M |
DRMA | Dermata Therapeutics | 0.94% | 3.4M |
You can purchase shares of NeuBase Therapeutics (NASDAQ: NBSE) through any online brokerage.
Other companies in NeuBase Therapeutics’s space includes: Plus Therapeutics (NASDAQ:PSTV), Panbela Therapeutics (NASDAQ:PBLA), Tharimmune (NASDAQ:THAR), Dermata Therapeutics (NASDAQ:DRMA) and Biocept (NASDAQ:BIOC).
The latest price target for NeuBase Therapeutics (NASDAQ: NBSE) was reported by Oppenheimer on Friday, October 21, 2022. The analyst firm set a price target for 0.00 expecting NBSE to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
The stock price for NeuBase Therapeutics (NASDAQ: NBSE) is $0.85 last updated Today at October 2, 2023 at 9:06 AM UTC.
There is no dividend information for NeuBase Therapeutics.
NeuBase Therapeutics’s Q4 earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for NeuBase Therapeutics.
NeuBase Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
NeuBase Therapeutics Stock (NASDAQ: NBSE) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.1.751K / 2.327M | Mkt Cap3.170M |
Day Range- - - | 52 Wk Range0.605 - 8.700 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2022-10-21 | Oppenheimer | Hartaj Singh | Downgrades | OutperformPerform | - | - | - |
2022-10-18 | RBC Capital | Leonid Timashev | Downgrades | OutperformSector Perform | Lowers | 12.00 | 1.00 |
2022-10-17 | Chardan Capital | Keay Nakae | Downgrades | BuyNeutral | - | - | - |
2022-08-12 | Chardan Capital | Keay Nakae | Maintains | Buy | Lowers | 9.00 | 7.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
NBSE | NeuBase Therapeutics | -2.28% | 3.2M |
PSTV | Plus Therapeutics | -5.22% | 3.7M |
PBLA | Panbela Therapeutics | -1.53% | 3.8M |
THAR | Tharimmune | -7.5% | 3.3M |
DRMA | Dermata Therapeutics | 0.94% | 3.4M |
You can purchase shares of NeuBase Therapeutics (NASDAQ: NBSE) through any online brokerage.
Other companies in NeuBase Therapeutics’s space includes: Plus Therapeutics (NASDAQ:PSTV), Panbela Therapeutics (NASDAQ:PBLA), Tharimmune (NASDAQ:THAR), Dermata Therapeutics (NASDAQ:DRMA) and Biocept (NASDAQ:BIOC).
The latest price target for NeuBase Therapeutics (NASDAQ: NBSE) was reported by Oppenheimer on Friday, October 21, 2022. The analyst firm set a price target for 0.00 expecting NBSE to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
The stock price for NeuBase Therapeutics (NASDAQ: NBSE) is $0.85 last updated Today at October 2, 2023 at 9:06 AM UTC.
There is no dividend information for NeuBase Therapeutics.
NeuBase Therapeutics’s Q4 earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for NeuBase Therapeutics.
NeuBase Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
NeuBase Therapeutics Stock (NASDAQ: NBSE) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.1.751K / 2.327M | Mkt Cap3.170M |
Day Range- - - | 52 Wk Range0.605 - 8.700 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2022-10-21 | Oppenheimer | Hartaj Singh | Downgrades | OutperformPerform | - | - | - |
2022-10-18 | RBC Capital | Leonid Timashev | Downgrades | OutperformSector Perform | Lowers | 12.00 | 1.00 |
2022-10-17 | Chardan Capital | Keay Nakae | Downgrades | BuyNeutral | - | - | - |
2022-08-12 | Chardan Capital | Keay Nakae | Maintains | Buy | Lowers | 9.00 | 7.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
NBSE | NeuBase Therapeutics | -2.28% | 3.2M |
PSTV | Plus Therapeutics | -5.22% | 3.7M |
PBLA | Panbela Therapeutics | -1.53% | 3.8M |
THAR | Tharimmune | -7.5% | 3.3M |
DRMA | Dermata Therapeutics | 0.94% | 3.4M |
You can purchase shares of NeuBase Therapeutics (NASDAQ: NBSE) through any online brokerage.
Other companies in NeuBase Therapeutics’s space includes: Plus Therapeutics (NASDAQ:PSTV), Panbela Therapeutics (NASDAQ:PBLA), Tharimmune (NASDAQ:THAR), Dermata Therapeutics (NASDAQ:DRMA) and Biocept (NASDAQ:BIOC).
The latest price target for NeuBase Therapeutics (NASDAQ: NBSE) was reported by Oppenheimer on Friday, October 21, 2022. The analyst firm set a price target for 0.00 expecting NBSE to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
The stock price for NeuBase Therapeutics (NASDAQ: NBSE) is $0.85 last updated Today at October 2, 2023 at 9:06 AM UTC.
There is no dividend information for NeuBase Therapeutics.
NeuBase Therapeutics’s Q4 earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for NeuBase Therapeutics.
NeuBase Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
NeuBase Therapeutics Stock (NASDAQ: NBSE) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.1.751K / 2.327M | Mkt Cap3.170M |
Day Range- - - | 52 Wk Range0.605 - 8.700 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2022-10-21 | Oppenheimer | Hartaj Singh | Downgrades | OutperformPerform | - | - | - |
2022-10-18 | RBC Capital | Leonid Timashev | Downgrades | OutperformSector Perform | Lowers | 12.00 | 1.00 |
2022-10-17 | Chardan Capital | Keay Nakae | Downgrades | BuyNeutral | - | - | - |
2022-08-12 | Chardan Capital | Keay Nakae | Maintains | Buy | Lowers | 9.00 | 7.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
NBSE | NeuBase Therapeutics | -2.28% | 3.2M |
PSTV | Plus Therapeutics | -5.22% | 3.7M |
PBLA | Panbela Therapeutics | -1.53% | 3.8M |
THAR | Tharimmune | -7.5% | 3.3M |
DRMA | Dermata Therapeutics | 0.94% | 3.4M |
You can purchase shares of NeuBase Therapeutics (NASDAQ: NBSE) through any online brokerage.
Other companies in NeuBase Therapeutics’s space includes: Plus Therapeutics (NASDAQ:PSTV), Panbela Therapeutics (NASDAQ:PBLA), Tharimmune (NASDAQ:THAR), Dermata Therapeutics (NASDAQ:DRMA) and Biocept (NASDAQ:BIOC).
The latest price target for NeuBase Therapeutics (NASDAQ: NBSE) was reported by Oppenheimer on Friday, October 21, 2022. The analyst firm set a price target for 0.00 expecting NBSE to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
The stock price for NeuBase Therapeutics (NASDAQ: NBSE) is $0.85 last updated Today at October 2, 2023 at 9:06 AM UTC.
There is no dividend information for NeuBase Therapeutics.
NeuBase Therapeutics’s Q4 earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for NeuBase Therapeutics.
NeuBase Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.